Ravuconazole

Ravuconazole

Clinical data
ATC code	None
Identifiers
IUPAC name 4-[2-[(2R,3R)-3-(2,4-Difluorophenyl)-3-hydroxy-4-(1,2,4-triazol-1-yl)butan-2-yl]-1,3-thiazol-4-yl]benzonitrile
CAS Number	182760-06-1 Y
PubChem CID	467825
ChemSpider	411041 N
UNII	95YH599JWV
ChEMBL	CHEMBL294029 N
NIAID ChemDB	057176
Chemical and physical data
Formula	C22H17F2N5OS
Molar mass	437.465086 g/mol
3D model (Jmol)	Interactive image
SMILES C[C@@H](C1=NC(=CS1)C2=CC=C(C=C2)C#N)[C@](CN3C=NC=N3)(C4=C(C=C(C=C4)F)F)O
InChI InChI=1S/C22H17F2N5OS/c1-14(21-28-20(10-31-21)16-4-2-15(9-25)3-5-16)22(30,11-29-13-26-12-27-29)18-7-6-17(23)8-19(18)24/h2-8,10,12-14,30H,11H2,1H3/t14-,22+/m0/s1 N Key:OPAHEYNNJWPQPX-RCDICMHDSA-N N
NY (what is this?)

Ravuconazole (codenamed BMS-207147 and ER-30346) is a potent triazole antifungal, being developed by Bristol-Myers Squibb, that is currently in phase I/II clinical trials. The drug has shown to have a similar spectrum of activity to voriconazole, with an increased half-life. However, ravuconazole has limited activity against species of Fusarium, Scedosporium, and Zygomycetes.